Press Releases

Wan Yang Feng, Ph.D. has been appointed Director of Bioanalytic and Metabolism of Bridge Pharmaceutical's Preclinical Laboratory in Beijing

October 6, 2006 - San Francisco, CA

Prior to joining Bridge, Dr. Feng worked in Novartis Institutes for BioMedical Research (NIBR) (formerly Chiron) for more than five years. During his tenure at NIBR, he was responsible for drug metabolism, pharmacokinetics and bioanalytical chemistry. His work played critical roles in characterizing ADME/PK properties of antibacterial and cancerous drugs from hit-to-lead to IND filing, as well as early phase I and II clinical trials for several discovery and development projects. He was also a manager of Chiron's large mass spectrometry laboratory. "We are extremely pleased to have someone of Dr. Feng's caliber joining our scientific team in Beijing. His technical expertise and NIBR/Chiron experience reinforces our goal to provide fully FDA compliant preclinical studies in our US-level GLP laboratory in Beijing," said the EVP and CTO of Bridge.

About Pharmaron

Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com.